FreeTheAI

Ocugen Licenses OCU400 to Roots Pharmaceutical in $259M MENA Deal

MixedMedium impact
OCGN$0.8854 −6.52%

Ocugen, Inc. (OCGN) has entered into an exclusive licensing agreement with Roots Pharmaceutical to commercialize its drug candidate, OCU400, across the Middle East and North Africa region. Under the terms of the deal, Ocugen could receive up to $4 million in initial milestone payments alongside up to $255 million in milestone payments tied to commercial sales.

The agreement allows Ocugen to expand the geographic reach of OCU400 into key international markets without building out regional sales operations. In addition to potential milestone payments totaling up to $259 million, Ocugen will maintain manufacturing rights to supply OCU400 and will receive a 22% royalty on net sales across the territory.

Investors are watching for upcoming clinical trial milestones that could trigger these commercial rights. A Phase 3 topline readout for OCU400 is expected in the first quarter of 2027. Meanwhile, shares of Ocugen were down 6.52% at $0.8854 following the announcement.

Key points

  • Ocugen signed an exclusive MENA licensing agreement for OCU400 with Roots Pharmaceutical.
  • The deal includes up to $4 million in initial milestones and up to $255 million in sales milestones.
  • Ocugen retains manufacturing rights and will earn a 22% royalty on net sales in the region.
  • Topline results from the Phase 3 trial of OCU400 are expected in the first quarter of 2027.
  • Ocugen shares fell 6.52% to $0.8854 in recent market trading.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What are the terms of Ocugen's OCU400 deal with Roots Pharmaceutical?

Ocugen will receive up to $4 million in initial milestones, up to $255 million in sales milestones, and 22% royalties on net sales in the MENA region, while remaining responsible for product supply.

When is the Phase 3 data for OCU400 expected?

Topline Phase 3 results for OCU400 are scheduled for release in the first quarter of 2027.

How did Ocugen stock react to the licensing news?

Ocugen shares fell 6.52% to $0.8854 following the news.